Peptide
Prostamax
Prostamax (KEDP) is a synthetic tetrapeptide composed of lysine, glutamic acid, aspartic acid and proline. It is studied in laboratory research involving peptide bioregulation, chromatin organisation, cellular ageing and tissue-specific cellular processes.
Research Use Only — Not For Human Consumption
Product Description
Prostamax (Lys-Glu-Asp-Pro / KEDP) is a synthetic short-chain tetrapeptide belonging to the family of compounds commonly described as peptide bioregulators.
Laboratory research involving Prostamax has focused primarily on its interaction with chromatin structure and cellular processes associated with ageing. In-vitro studies using cultured human lymphocytes have examined changes in heterochromatin organisation, nucleolar organiser regions and other chromosome-associated parameters following exposure to KEDP.
Additional preclinical research involving short peptide bioregulators has investigated tissue-specific cellular responses in organotypic culture models, including prostate-derived tissue.
Prostamax may therefore be of interest to researchers studying:
- Peptide-mediated cellular regulation
- Chromatin organisation and gene-expression research
- Cellular ageing and senescence
- Tissue-specific peptide signalling
- Heterochromatin dynamics
- Short-chain peptide bioregulators
- Experimental prostate-tissue biology
The available evidence for Prostamax remains limited and predominantly preclinical. Published findings should not be interpreted as demonstrating therapeutic effects, safety or efficacy in humans.
For laboratory and research purposes only. Not for human consumption. Not intended to diagnose, treat, cure or prevent any disease.